The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201405000798226

Enrollment

Registered

2014-03-21

Start date

2014-03-25

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System liver cirrhosis

Interventions

Group 1 Slow flow rate: low sodium

Group II medium flow rate

Group III: rapid flow rate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1-the presence of tense ascites determined by clinical examination and abdominal ultrasound, requiring frequent therapeutic paracentesis

Exclusion criteria

Exclusion criteria: 1-arterial hypertension, history of coronary disease, cardiac failure, respiratory disease. 2-hepatic encephalopathy. 3-sepsis 4-spontaneous bacterial peritonitis (defined by polymorphonuclear cell count >250/mm3 in ascites 5-elevated creatinine concentration >1.5 mg/dL 6-gastrointestinal bleeding within 7 days before the study.

Design outcomes

Primary

Measure	Time frame
paracentesis induced circulatory dysfunction (PICD) development	—

Countries

Egypt

Contacts

Public ContactAyman Alsebaey Alghoraieb

Lecturer of Hepatology, National Liver Institute, Menoufiya University, Shebeen El-Kom, Egypt

aymanalsebaey@yahoo.com+201003751248

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026